Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Raziel Therapeutics and Fosun Pharma Announce Positive Phase 3 Results for RZL-012 in Submental Fat Reduction, Clearing the Path to a China NDA Filing
Raziel Therapeutics ("Raziel"), a pharmaceutical company developing next-generation prescription products for the aesthetics market, today announced positive results from its Phase 3 registration trial in China evaluating RZL-012 for the reduction of subm
Read more
Report
Raziel Therapeutics and Fosun Pharma Announce Positive Phase 3 Results for RZL-012 in Submental Fat Reduction, Clearing the Path to a China NDA Filing
Read more
Report
Why authority is the attack surface AI security keeps missing
Tide's new MCP server helps coding agents integrate security built on authority that appears only when identity, policy, context, and intent align.
Read more
Report
Raziel and Fosun Pharma (by JuveStar an affiliate company of Fosun Pharma) Initiate Phase 3 Registration Trial in China for Submental Fat Reduction ("double chin")
/PRNewswire/ -- Raziel Therapeutics, a pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market,...
Read more
Report
Wife of Terror Victim Rabbi Raziel Shevach HY"D Chooses Life And Helping Others
It has been about ten months since the terror attack in Shomron that claimed the life of Rabbi Shevach Raziel HY"D, 35, a resident of Gilad Farm in Shomron, a father of six, a mohel and community activist. In fact, he was heading back home from checking a
Read more
Report
An injection that removes double chin and side fat will be released soon Philippe Sejong-Raziel, Chairman of the Board of Directors , is developing a fat-reducing injection that reduces fat in only the desired area. Aiming to launch in the US and China in 2027. Effective when combined with Wegobi. Market to reach 4.3 billion by 2030.
An injection that removes double chin and side fat will be released soon
Read more
Report
